Effects of Aldose Reductase Inhibitors and Galactose Withdrawal on Fluorescein Angiographic Lesions in Galactose-Fed Dogs

Michael Cusick, Emily Y. Chew, Frederick Ferris, Terry A. Cox, Chi Chao Chan, Peter F. Kador

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: To assess the effect of aldose reductase inhibitor (ARI) M79175 (2-methyl-6-fluoro-spiro-chroman-4-5′-imidazolidine-2′, 4′-dione) administration and galactose withdrawal on the progression of retinal changes using fluorescein angiography in galactose-fed dogs. Methods: Thirty male beagles were randomized into 4 groups. Three dogs were fed a normal control diet containing 30% nonnutritive fiber for 74 months (control group), 11 dogs a 30% galactose diet for 74 months (continuous galactose group), 8 dogs a 30% galactose diet for 36 months followed by replacement with a normal diet for 36 months (galactose withdrawal group), and 8 dogs a 30% galactose diet supplemented with M79175 for 34 months followed by replacement with a normal diet and removal of M79175 treatment for 38 months (ARI-treated galactose withdrawal group). Stereoscopic color fundus photography and fluorescein angiography, performed at baseline and follow-up, were assessed for the clinical development of retinopathy, including the first appearance of hyperfluorescence, varying severity of retinal nonperfusion, and retinal neovascularization. Histopathologic features were examined in selected dogs. Results: All dogs in the 3 groups fed the 30% galactose diet developed areas of hyperfluorescence and nonperfusion. Of these dogs, only those supplemented with the ARI did not develop areas of nonperfusion greater than or equal to half the field and retinal neovascularization. Parametric survival analysis showed significant differences (galactose withdrawal group vs ARI-treated galactose withdrawal group) in the median times to the development of nonperfusion greater than or equal to half the field (P=.003) and retinal neovascularization (P=.03). Conclusion: Normalization of glycemic control with galactose withdrawal and ARI treatment may delay the onset and progression of retinal lesions in galactose-fed dogs. Clinical Relevance: Perfect glycemic control after a period of poor control does not completely prevent the progression of retinal lesions. Therapy with ARIs may potentially be important in the prevention of retinal lesions associated with diabetic eye disease.

Original languageEnglish (US)
Pages (from-to)1745-1751
Number of pages7
JournalArchives of Ophthalmology
Volume121
Issue number12
DOIs
StatePublished - Dec 1 2003

Fingerprint

Aldehyde Reductase
Fluorescein
Galactose
Dogs
Diet
Retinal Neovascularization
Fluorescein Angiography
Chromans
Eye Diseases
Photography
Survival Analysis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effects of Aldose Reductase Inhibitors and Galactose Withdrawal on Fluorescein Angiographic Lesions in Galactose-Fed Dogs. / Cusick, Michael; Chew, Emily Y.; Ferris, Frederick; Cox, Terry A.; Chan, Chi Chao; Kador, Peter F.

In: Archives of Ophthalmology, Vol. 121, No. 12, 01.12.2003, p. 1745-1751.

Research output: Contribution to journalArticle

Cusick, Michael ; Chew, Emily Y. ; Ferris, Frederick ; Cox, Terry A. ; Chan, Chi Chao ; Kador, Peter F. / Effects of Aldose Reductase Inhibitors and Galactose Withdrawal on Fluorescein Angiographic Lesions in Galactose-Fed Dogs. In: Archives of Ophthalmology. 2003 ; Vol. 121, No. 12. pp. 1745-1751.
@article{3707ded04ec0415ebf3e4cb93ae54789,
title = "Effects of Aldose Reductase Inhibitors and Galactose Withdrawal on Fluorescein Angiographic Lesions in Galactose-Fed Dogs",
abstract = "Objective: To assess the effect of aldose reductase inhibitor (ARI) M79175 (2-methyl-6-fluoro-spiro-chroman-4-5′-imidazolidine-2′, 4′-dione) administration and galactose withdrawal on the progression of retinal changes using fluorescein angiography in galactose-fed dogs. Methods: Thirty male beagles were randomized into 4 groups. Three dogs were fed a normal control diet containing 30{\%} nonnutritive fiber for 74 months (control group), 11 dogs a 30{\%} galactose diet for 74 months (continuous galactose group), 8 dogs a 30{\%} galactose diet for 36 months followed by replacement with a normal diet for 36 months (galactose withdrawal group), and 8 dogs a 30{\%} galactose diet supplemented with M79175 for 34 months followed by replacement with a normal diet and removal of M79175 treatment for 38 months (ARI-treated galactose withdrawal group). Stereoscopic color fundus photography and fluorescein angiography, performed at baseline and follow-up, were assessed for the clinical development of retinopathy, including the first appearance of hyperfluorescence, varying severity of retinal nonperfusion, and retinal neovascularization. Histopathologic features were examined in selected dogs. Results: All dogs in the 3 groups fed the 30{\%} galactose diet developed areas of hyperfluorescence and nonperfusion. Of these dogs, only those supplemented with the ARI did not develop areas of nonperfusion greater than or equal to half the field and retinal neovascularization. Parametric survival analysis showed significant differences (galactose withdrawal group vs ARI-treated galactose withdrawal group) in the median times to the development of nonperfusion greater than or equal to half the field (P=.003) and retinal neovascularization (P=.03). Conclusion: Normalization of glycemic control with galactose withdrawal and ARI treatment may delay the onset and progression of retinal lesions in galactose-fed dogs. Clinical Relevance: Perfect glycemic control after a period of poor control does not completely prevent the progression of retinal lesions. Therapy with ARIs may potentially be important in the prevention of retinal lesions associated with diabetic eye disease.",
author = "Michael Cusick and Chew, {Emily Y.} and Frederick Ferris and Cox, {Terry A.} and Chan, {Chi Chao} and Kador, {Peter F.}",
year = "2003",
month = "12",
day = "1",
doi = "10.1001/archopht.121.12.1745",
language = "English (US)",
volume = "121",
pages = "1745--1751",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Effects of Aldose Reductase Inhibitors and Galactose Withdrawal on Fluorescein Angiographic Lesions in Galactose-Fed Dogs

AU - Cusick, Michael

AU - Chew, Emily Y.

AU - Ferris, Frederick

AU - Cox, Terry A.

AU - Chan, Chi Chao

AU - Kador, Peter F.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Objective: To assess the effect of aldose reductase inhibitor (ARI) M79175 (2-methyl-6-fluoro-spiro-chroman-4-5′-imidazolidine-2′, 4′-dione) administration and galactose withdrawal on the progression of retinal changes using fluorescein angiography in galactose-fed dogs. Methods: Thirty male beagles were randomized into 4 groups. Three dogs were fed a normal control diet containing 30% nonnutritive fiber for 74 months (control group), 11 dogs a 30% galactose diet for 74 months (continuous galactose group), 8 dogs a 30% galactose diet for 36 months followed by replacement with a normal diet for 36 months (galactose withdrawal group), and 8 dogs a 30% galactose diet supplemented with M79175 for 34 months followed by replacement with a normal diet and removal of M79175 treatment for 38 months (ARI-treated galactose withdrawal group). Stereoscopic color fundus photography and fluorescein angiography, performed at baseline and follow-up, were assessed for the clinical development of retinopathy, including the first appearance of hyperfluorescence, varying severity of retinal nonperfusion, and retinal neovascularization. Histopathologic features were examined in selected dogs. Results: All dogs in the 3 groups fed the 30% galactose diet developed areas of hyperfluorescence and nonperfusion. Of these dogs, only those supplemented with the ARI did not develop areas of nonperfusion greater than or equal to half the field and retinal neovascularization. Parametric survival analysis showed significant differences (galactose withdrawal group vs ARI-treated galactose withdrawal group) in the median times to the development of nonperfusion greater than or equal to half the field (P=.003) and retinal neovascularization (P=.03). Conclusion: Normalization of glycemic control with galactose withdrawal and ARI treatment may delay the onset and progression of retinal lesions in galactose-fed dogs. Clinical Relevance: Perfect glycemic control after a period of poor control does not completely prevent the progression of retinal lesions. Therapy with ARIs may potentially be important in the prevention of retinal lesions associated with diabetic eye disease.

AB - Objective: To assess the effect of aldose reductase inhibitor (ARI) M79175 (2-methyl-6-fluoro-spiro-chroman-4-5′-imidazolidine-2′, 4′-dione) administration and galactose withdrawal on the progression of retinal changes using fluorescein angiography in galactose-fed dogs. Methods: Thirty male beagles were randomized into 4 groups. Three dogs were fed a normal control diet containing 30% nonnutritive fiber for 74 months (control group), 11 dogs a 30% galactose diet for 74 months (continuous galactose group), 8 dogs a 30% galactose diet for 36 months followed by replacement with a normal diet for 36 months (galactose withdrawal group), and 8 dogs a 30% galactose diet supplemented with M79175 for 34 months followed by replacement with a normal diet and removal of M79175 treatment for 38 months (ARI-treated galactose withdrawal group). Stereoscopic color fundus photography and fluorescein angiography, performed at baseline and follow-up, were assessed for the clinical development of retinopathy, including the first appearance of hyperfluorescence, varying severity of retinal nonperfusion, and retinal neovascularization. Histopathologic features were examined in selected dogs. Results: All dogs in the 3 groups fed the 30% galactose diet developed areas of hyperfluorescence and nonperfusion. Of these dogs, only those supplemented with the ARI did not develop areas of nonperfusion greater than or equal to half the field and retinal neovascularization. Parametric survival analysis showed significant differences (galactose withdrawal group vs ARI-treated galactose withdrawal group) in the median times to the development of nonperfusion greater than or equal to half the field (P=.003) and retinal neovascularization (P=.03). Conclusion: Normalization of glycemic control with galactose withdrawal and ARI treatment may delay the onset and progression of retinal lesions in galactose-fed dogs. Clinical Relevance: Perfect glycemic control after a period of poor control does not completely prevent the progression of retinal lesions. Therapy with ARIs may potentially be important in the prevention of retinal lesions associated with diabetic eye disease.

UR - http://www.scopus.com/inward/record.url?scp=0344305690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344305690&partnerID=8YFLogxK

U2 - 10.1001/archopht.121.12.1745

DO - 10.1001/archopht.121.12.1745

M3 - Article

C2 - 14662595

AN - SCOPUS:0344305690

VL - 121

SP - 1745

EP - 1751

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 12

ER -